SCHEMBL2386265

SCHEMBL2386265

O=C(Nc1c[c]ccc1)C1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.48
GAA P10253 3/20 0.48
HPGD P15428 2/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ULK1 O75385 1/20 0.46
F10 P00742 7/20 0.46
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
GFER P55789 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.43
FLT3 P36888 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921374 0.89 GAA (0.56) GAAHPGDUSP2LMNAHTT
SCHEMBL6615592 0.86 HPGD (0.63) GAAHPGDUSP2LMNAHTT
SCHEMBL3814690 0.86 HPGD (0.58) GAAHPGDUSP2LMNAHTT
SCHEMBL693444 0.85 HPGD (0.66) GAAHPGDLMNASMN1; SMN2NPSR1
SCHEMBL15528879 0.81 SIRT2 (0.52) SIRT2GAAHPGDUSP2LMNA
SCHEMBL4141969 0.81 HPGD (0.69) SIRT2GAAHPGDLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL8508299 0.80 HPGD (0.67) SIRT2GAAHPGDLMNASMN1; SMN2
SCHEMBL1720856 0.76 MGLL (0.56) GAAHPGDUSP2LMNAHTT
SCHEMBL6756210 0.75 HPGD (0.45) GAAHPGDMEN1KMT2ANPSR1
SCHEMBL6757892 0.75 HPGD (0.49) GAAHPGDLMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017611-B2 Pyridine and pyrazine derivatives -083 ASTRAZENECA AB (SE) 2011-09-13 US disclosed
EP-2215085-B1 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-09-07 EP disclosed
CN-101910158-A Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders ASTRAZENECA AB 2010-12-08 CN disclosed
EP-2215085-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-11 EP disclosed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 US disclosed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 MKI67, CCND3, CCND1 SIRT2 635/4885GAA 3801/4885HPGD 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.